MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$4,084K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from registered direct ...
Proceeds from warrant exercise
Depreciation and amortization
Proceeds from sale of stock, net...
Negative Cash Flow Breakdown
Net loss
Accounts payable and accrued exp...
Abandonment and expiration of pa...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Loss (gain) on sale of marketable investments
-
-
-
18
Depreciation of property and equipment
-
-19
9
19
Amortization of patent, trademark rights
-
-105
45
94
Equity-based compensation
-
-
0
60
Amortization of debt discount and other expenses
-
183
-
-
Accrued expenses
-
-223
287
-33
Non-cash lease expense
-
72
-59
-81
Funds receivable from new jersey net operating loss
-
-
-
0
Other assets
-
700
11
-761
Net loss
-3,788
6,760
-3,284
-6,499
Gain on sale of marketable securities
-
-
17
-
Accounts payable
-
1,241
-2,570
914
Depreciation and amortization
571
-
-
-
Amortization of financial obligation
-
-
69
183
Loss (gain) on sale of marketable investments
-
-1
-
-
Abandonment and expiration of patents and trademark rights
-673
-
82
615
Loss on change in fair value of warrant liability
0
1,138
-670
-
Loss on issuance of warrants
0
3,945
-3,977
0
Non-cash gain on settlement of liability
-
-
-3,041
-
Prepaid expenses and other assets
27
127
-24
-9
Lease liability
-50
64
-56
-78
Accounts payable and accrued expenses
-1,359
-
-
-
Other receivables
0
-7
-
-
Net cash used in operating activities
-4,590
6,252
-5,079
-3,892
Proceeds from sale of marketable securities
-
-
296
2,026
Proceeds from sale of marketable investments
0
4
-
-
Purchase of marketable securities
-
-
0
91
Purchase of marketable investments
0
6
-
-
Purchase of patent and trademark rights
112
-248
0
283
Net cash (used in) provided by investing activities
-112
-1,985
296
1,652
Proceeds from issuance of common stock and warrants
-
-
7,314
-
Proceeds from sale of stock, net of issuance costs
537
1,634
-398
765
Proceeds from warrant exercise
3,577
2,156
-
-
Proceeds from note payable, net of issuance costs
-
-
0
250
Repayment of debt obligation
621
200
-
-
Repayment of debt with cash
-
-
660
-
Proceeds from registered direct offerings
5,293
-
-
-
Proceeds from issuance of equity warrants
-
-
-
0
Proceeds from equity line of credit
-
-
398
-
Proceeds from rights offering
0
1,630
-
-
Net cash provided by financing activities
8,786
-2,082
6,654
1,015
Net increase (decrease) in cash and cash equivalents
4,084
2,185
1,871
-1,225
Cash and cash equivalents at beginning of period
2,347
2,347
1,701
-
Cash and cash equivalents at end of period
9,900
5,816
2,347
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from registered
direct offerings
$5,293K
Proceeds from warrant
exercise
$3,577K
Proceeds from sale of
stock, net of issuance...
$537K
(-29.80%↓ Y/Y)
Net cash provided by
financing activities
$8,786K
(765.62%↑ Y/Y)
Canceled cashflow
$621K
Net increase
(decrease) in cash and cash...
$4,084K
(433.39%↑ Y/Y)
Canceled cashflow
$4,702K
Repayment of debt
obligation
$621K
something is missing
$736K
Depreciation and
amortization
$571K
Net cash used in
operating activities
-$4,590K
(-17.93%↓ Y/Y)
Net cash (used in)
provided by investing...
-$112K
(-106.78%↓ Y/Y)
Canceled cashflow
$1,307K
Net loss
-$3,788K
(41.71%↑ Y/Y)
Accounts payable and
accrued expenses
-$1,359K
Purchase of patent and
trademark rights
$112K
(-60.42%↓ Y/Y)
Abandonment and expiration
of patents and...
-$673K
(-209.43%↓ Y/Y)
Lease liability
-$50K
(35.90%↑ Y/Y)
Prepaid expenses and
other assets
$27K
(400.00%↑ Y/Y)
Buy us a coffee
AIM ImmunoTech Inc. (AIM)
AIM ImmunoTech Inc. (AIM)